ENTERA BIO LTD. Employee Benefits and Share-based Compensation
ENTERA BIO LTD. (ENTX) reported Employee Benefits and Share-based Compensation of $377.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2026-08-07
- ENTERA BIO LTD. employee benefits and share-based compensation for the quarter ending 2026-06-30 was $377.00K, a 28.23% increase year-over-year.
- ENTERA BIO LTD. employee benefits and share-based compensation for the quarter ending 2026-03-31 was $313.00K, a 77.84% increase year-over-year.
- ENTERA BIO LTD. employee benefits and share-based compensation for the quarter ending 2025-12-31 was $344.00K, a 74.62% increase year-over-year.
- ENTERA BIO LTD. employee benefits and share-based compensation for the quarter ending 2025-09-30 was $329.00K, a 43.67% increase year-over-year.
- ENTERA BIO LTD. employee benefits and share-based compensation for fiscal 2025 was $1.14M, a 36.07% increase from fiscal 2024.
- ENTERA BIO LTD. employee benefits and share-based compensation for fiscal 2024 was $840.00K.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $377.00K 10-Q · filed 2026-08-07 | $690.00K 10-Q · filed 2026-08-07 | $1.03M derived: sum of 3 quarters · filed 2026-08-07 | $1.36M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $313.00K 10-Q · filed 2026-05-08 | $657.00K derived: sum of 2 quarters · filed 2026-05-08 | $986.00K derived: sum of 3 quarters · filed 2026-05-08 | $1.28M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $344.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $673.00K derived: sum of 2 quarters · filed 2026-03-27 | $967.00K derived: sum of 3 quarters · filed 2026-08-07 | $1.14M 10-K · filed 2026-03-27 |
| 2025-09-30 | $329.00K 10-Q · filed 2025-11-14 | $623.00K derived: sum of 2 quarters · filed 2026-08-07 | $799.00K 10-Q · filed 2025-11-14 | $996.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $294.00K 10-Q · filed 2026-08-07 | $470.00K 10-Q · filed 2026-08-07 | $667.00K derived: sum of 3 quarters · filed 2026-08-07 | $896.00K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $176.00K 10-Q · filed 2026-05-08 | $373.00K derived: sum of 2 quarters · filed 2026-05-08 | $602.00K derived: sum of 3 quarters · filed 2026-05-08 | $930.00K derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $426.00K derived: sum of 2 quarters · filed 2026-03-27 | $754.00K derived: sum of 3 quarters · filed 2026-03-27 | $840.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $229.00K 10-Q · filed 2025-11-14 | $557.00K derived: sum of 2 quarters · filed 2025-11-14 | $643.00K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $328.00K 10-Q · filed 2025-08-08 | $414.00K 10-Q · filed 2025-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |